Quarterly report pursuant to Section 13 or 15(d)

CONDENSED CONSOLIDATED BALANCE SHEETS

v3.19.1
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)
Mar. 31, 2018
Dec. 31, 2017
Current assets    
Cash $ 231 $ 142
Prepaid Expenses 4,419 3,006
Total current assets 4,650 3,148
Total Assets 4,650 3,148
Current liabilities    
Accounts payable 160,197 270,851
Accrued expenses 508,164 493,164
Accrued interest payable 424,676 382,302
Related party payables 1,187,273 1,026,819
Notes payable - current - related parties [1] 649,611 630,575
Notes payable - current - non related parties 163,574 163,574
Total current liabilities 3,093,495 2,967,285
Total Liabilities 3,093,495 2,967,285
Stockholders' Deficit    
Preferred stock, value
Common stock, $.00001 par value; 800,000,000 shares authorized; 109,501,078 and 109,409,930 shares issued and outstanding as of March 31, 2018 and December 31, 2017, respectively 1,097 1,096
Additional paid-in capital 14,804,212 14,785,051
Accumulated deficit (17,846,220) (17,703,171)
Total Transbiotec, Inc. stockholders' deficit (3,040,897) (2,917,010)
Noncontrolling interest (47,948) (47,127)
Total Stockholders' Deficit (3,088,845) (2,964,137)
Total Liabilities and Stockholders' Deficit 4,650 3,148
Series A Preferred Stock [Member]    
Stockholders' Deficit    
Preferred stock, value $ 14 $ 14
[1] Includes unamortized debt issuance costs related to detached warrants of $21,233 and $19,969 at March 31, 2018 and December 31, 2017, respectively.